Precision Medicine

Joel Neal, MD, PhD, and Alexander I. Spira, MD, PhD, FACP, talk about the role of EGFR, particularly exon 20 insertion, in NSCLC growth and progression, and review the mechanism of action and current safety and efficacy data from the mobocertinib trial.

Experts discuss the role of CD19 in the therapeutic landscape for patients with transplant-ineligible relapsed/refractory DLBCL.

A discussion ofJAK2-directed therapies, their roles in treatment, and the key clinical trials guiding their use in myeloproliferative neoplasms. Also discussed are some relevant data recently presented at ASCO.

Jason M. Melear, MD, and Ian W. Flinn, MD, PhD, discuss the role of PI3K inhibitors in the management of R/R follicular lymphoma and marginal zone lymphoma.

Experts discuss advances in gastrointestinal stromal tumors (GIST) and dive into the evolving landscape and ongoing unmet needs.

Experts in genitourinary oncology discuss emerging research surrounding the clinical utility of phenotypic biomarkers, such as prostate-specific membrane antigen (PSMA), for use in the treatment of metastatic castration-resistant prostate cancer.

A panel discusses the role of TKI combination therapies for patients with advanced renal cell carcinoma and how they have changed the treatment landscape.

A review of key relevant data on HER2-positive breast cancer from the 2020 SABCS Virtual Symposium.

Expert physicians discuss the rationale behind the clinical use of JAK inhibitors in acute GvHD (graft-versus-host disease), and provide an overview of recent clinical trial data for this treatment approach.

An in-depth discussion on the targeting of specific molecular pathways with newer, novel therapies to better manage patients with liver cancer.

Experts from Sarah Cannon Research Institute talk about the expanding role of targeted treatment options in early HER2+ breast cancer.

A discussion on a novel therapeutic target for treatment, known as exportin 1 (XPO1), and the first selective nuclear export inhibitor to enter clinical use for patients who have developed relapse after IMiD and protease inhibitor therapies.

Dr Mark Pegram and Dr Julie Gralow discuss treatment options in relapsed/refractory HER2+ metastatic breast cancer.

Key opinion leaders discuss the evolving treatment paradigm for relapsed/refractory gastrointestinal stromal tumors, and provide an overview of supplemental data presented at the ASCO (American Society of Clinical Oncology) 2020 Annual Meeting.

Shared insight on recent advances in KRAS-mutant NSCLC, with a focus on new therapies on the horizon.

Jennifer R. Brown, MD, PhD, and Alan Skarbnik, MD, describe the rationale for treating chronic lymphocytic leukemia with BTK inhibition, and explore current trends in data that impact treatment selection.

Experts in the management of diffuse large B-cell lymphoma (DLBCL) discuss the use of novel CD19-antibody mono- and combination therapies to treat relapsed/refractory subpopulations.

Ovarian Cancer

Lung Cancer

General Cancer

Skin Cancer

Hodgkin Lymphoma

Leukemia

Chronic Myeloid Leukemia

Lymphoma

General Cancer